# Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan

> **NCT04325217** · — · ACTIVE_NOT_RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 586 (actual)

## Conditions studied

- Lung Diseases, Interstitial

## Interventions

- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT04325217
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-27
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 586 (ACTUAL)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04325217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04325217, "Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04325217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*